OUP user menu

Hereditary dystonia and parkinsonism: two sides of the same coin?

Anne Weissbach, Christine Klein
DOI: http://dx.doi.org/10.1093/brain/awu181 2402-2404 First published online: 13 August 2014

This scientific commentary refers to ‘Parkinson’s disease in GTP cyclohydrolase 1 mutation carriers’, by Mencacci et al. (doi:10/1093/brain/awu179).

A number of inherited disorders are marked by combined dystonia and parkinsonism, and the genetic basis of many of these has now been identified. They include putative ‘neurofunctional’ conditions with dystonia-parkinsonism, such as DOPA-responsive dystonia caused by mutations in the GTP cyclohydrolase 1 (GCH1) gene, as well as neurodegenerative diseases that present with predominant parkinsonism, frequently accompanied by dystonic features, i.e. ‘parkinsonism-dystonia’, as seen in carriers of parkin (PARK2) and PINK1 mutations. Because dystonia can be the presenting sign in parkinsonism-dystonias (Grünewald et al., 2013) and, conversely, patients with DOPA-responsive dystonia can present with isolated parkinsonism (Grimes et al., 2002; Tadic et al., 2012), it can be difficult to categorize individual patients solely on clinical grounds. The boundaries between dystonia and parkinsonism may thus be less well defined than previously thought, and this calls for detailed longitudinal phenotyping of patients. Indeed, despite the advent of next-generation sequencing and increased availability of diagnostic testing—resulting in a wealth of genetic data—systematic genotype–phenotype evaluations lag behind advances in genetics and have largely yet to be translated into clinical practice (Grünewald et al., 2013).

In this issue of Brain, Mencacci et al. elegantly address the phenomenon of prominent parkinsonism in carriers of GCH1 mutations (Mencacci et al., 2014). Prompted by their observation that relatives of patients with DOPA-responsive dystonia can present with pure ‘Parkinson’s disease’, they systematically collected and examined four such unrelated pedigrees harbouring GCH1 mutations and reviewed the literature for similar reports. This resulted in a total of eight cases from different ethnic backgrounds with predominant parkinsonism, all of whom had a mostly asymmetrical reduction in dopamine transporter density or fluorodopa uptake, in …

View Full Text